Argenx
ARGX
#455
Rank
C$77.19 B
Marketcap
C$1,234
Share price
3.37%
Change (1 day)
59.37%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2026 (TTM): C$2.07 Billion

According to Argenx 's latest financial reports the company's current earnings are C$4.66 Billion. In 2025 the company made an earning of C$1.80 Billion, an increase over its 2024 earnings that were of C$0.12 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) C$2.07 B14.94%
2025 C$1.80 B1400.64%
2024 C$0.12 B-127.97%
2023 -C$0.43 Billion-58.25%
2022 -C$1.03 Billion80.17%
2021 -C$0.58 Billion
2019 -C$0.29 Billion124.86%
2018 -C$0.13 Billion131.81%
2017 -C$53.81 Million
2015 -C$25.98 Million
2013 -C$15.72 Million